

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**202155Orig1s002**

**LABELING**

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.

ELIQUIS (apixaban) tablets for oral use  
Initial U.S. Approval: 2012

**WARNING: DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE**  
*See full prescribing information for complete boxed warning.*  
Discontinuing ELIQUIS places patients at an increased risk of thrombotic events. An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation. If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered. (2.4, 5.1)

**INDICATIONS AND USAGE**  
ELIQUIS is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1)

**DOSAGE AND ADMINISTRATION**  
• The recommended dose is 5 mg orally twice daily. (2.1)  
• In patients with at least 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. (2.2)

**DOSAGE FORMS AND STRENGTHS**  
• Tablets: 2.5 mg and 5 mg (3)

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**WARNING: DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE**

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
  - 2.1 Recommended Dose
  - 2.2 Dosage Adjustments
  - 2.3 Missed Dose
  - 2.4 Temporary Interruption for Surgery and Other Interventions
  - 2.5 Converting from or to ELIQUIS
  - 2.6 Hepatic Impairment
  - 2.7 Renal Impairment
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
  - 5.1 Increased Risk of Stroke with Discontinuation of ELIQUIS
  - 5.2 Bleeding
  - 5.3 Patients with Prosthetic Heart Valves
- 6 ADVERSE REACTIONS**
  - 6.1 Clinical Trials Experience
- 7 DRUG INTERACTIONS**
  - 7.1 Strong Dual Inhibitors of CYP3A4 and P-gp
  - 7.2 Strong Dual Inducers of CYP3A4 and P-gp
  - 7.3 Anticoagulants and Antiplatelet Agents

**CONTRAINDICATIONS**

- Active pathological bleeding (4)
- Severe hypersensitivity to ELIQUIS (4)

**WARNINGS AND PRECAUTIONS**

- ELIQUIS can cause serious, potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss. (5.2)
- Prosthetic heart valves: ELIQUIS use not recommended. (5.3)

**ADVERSE REACTIONS**

Most common adverse reactions (>1%) are related to bleeding. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**DRUG INTERACTIONS**

- Strong dual inhibitors of CYP3A4 and P-gp increase blood levels of apixaban: Reduce ELIQUIS dose to 2.5 mg or avoid concomitant use. (2.2, 7.1, 12.3)
- Simultaneous use of strong dual inducers of CYP3A4 and P-gp reduces blood levels of apixaban: Avoid concomitant use. (7.2, 12.3)

**USE IN SPECIFIC POPULATIONS**

- *Nursing Mothers*: Discontinue drug or discontinue nursing. (8.3)
- *Pregnancy*: Not recommended. (8.1)
- *Severe Hepatic Impairment*: Not recommended. (12.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 01/2014

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 End-Stage Renal Disease Patients Maintained with Hemodialysis

**10 OVERDOSAGE**

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES**

- 14.1 ARISTOTLE
- 14.2 AVERROES

**16 HOW SUPPLIED/STORAGE AND HANDLING**

**17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### **WARNING: DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE**

Discontinuing ELIQUIS places patients at an increased risk of thrombotic events. An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation. If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered [see *Dosage and Administration (2.4)* and *Warnings and Precautions (5.1)*].

## 1 INDICATIONS AND USAGE

ELIQUIS<sup>®</sup> (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Recommended Dose

The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily.

### 2.2 Dosage Adjustments

The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with any 2 of the following characteristics:

- age  $\geq$ 80 years
- body weight  $\leq$ 60 kg
- serum creatinine  $\geq$ 1.5 mg/dL

*CYP3A4 and P-gp inhibitors:* When ELIQUIS is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin), the recommended dose is 2.5 mg twice daily [see *Clinical Pharmacology (12.3)*].

In patients already taking 2.5 mg twice daily, coadministration of ELIQUIS with strong dual inhibitors of CYP3A4 and P-gp should be avoided.

## **2.3 Missed Dose**

If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.

## **2.4 Temporary Interruption for Surgery and Other Interventions**

ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.

## **2.5 Converting from or to ELIQUIS**

*Switching from warfarin to ELIQUIS:* Warfarin should be discontinued and ELIQUIS started when the international normalized ratio (INR) is below 2.0.

*Switching from ELIQUIS to warfarin:* ELIQUIS affects INR, so that initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.

*Switching between ELIQUIS and anticoagulants other than warfarin:* Discontinue one being taken and begin the other at the next scheduled dose.

## **2.6 Hepatic Impairment**

No dose adjustment is required in patients with mild hepatic impairment.

Because patients with moderate hepatic impairment may have intrinsic coagulation abnormalities and there is limited clinical experience with ELIQUIS in these patients, dosing recommendations cannot be provided [see *Clinical Pharmacology* (12.2)].

ELIQUIS is not recommended in patients with severe hepatic impairment [see *Clinical Pharmacology* (12.3)].

## **2.7 Renal Impairment**

The dosing adjustment for moderate renal impairment is described above [see *Dosage and Administration* (2.2)]. The recommended dose for patients with end-stage renal disease (ESRD) maintained on hemodialysis is 5 mg twice daily. Reduce dose to 2.5 mg twice daily if one of the following patient characteristics (age  $\geq$ 80 years or body weight  $\leq$ 60 kg) is present [see *Use in Specific Populations* (8.6) and *Clinical Pharmacology* (12.3)].

## **3 DOSAGE FORMS AND STRENGTHS**

- 2.5 mg, yellow, round, biconvex, film-coated tablets with “893” debossed on one side and “2½” on the other side.
- 5 mg, pink, oval-shaped, biconvex, film-coated tablets with “894” debossed on one side and “5” on the other side.

## **4 CONTRAINDICATIONS**

ELIQUIS is contraindicated in patients with the following conditions:

- Active pathological bleeding [see *Warnings and Precautions* (5.2) and *Adverse Reactions* (6.1)]
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see *Adverse Reactions* (6.1)]

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Increased Risk of Stroke with Discontinuation of ELIQUIS**

Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.